COO The Cooper Companies, Inc.

Activist campaigns tend to surface when a stock’s performance no longer matches its story, and The Cooper Companies, Inc. (NASDAQ:COO) is a case in point. In mid-September 2026, Jana Partners, which built its stake in the contact lens maker roughly a year ago. It began pushing Cooper to replace CEO Albert White and its board […]

Cooper Companies (COO) just opened The Vision Centre in Southampton, a global hub that brings together research, clinical work, pilot manufacturing, and advanced technology to help move new contact lens products toward market more quickly. The backdrop for this new hub is a share price that has retreated sharply over 2026. Cooper Companies has a 30 day share price return of down 23.8% and a year to date share price return of down 31.7%, while the 1 year total shareholder return is down 18%...

The Cooper Companies opens a global innovation hub in England and unveils six contact lens programs to support sustainable long-term growth.

With marginal growth across key metrics during the third quarter, The Cooper Companies Inc. (NASDAQ:COO) also finalized its strategic review process, which was initially announced in December last year. In Cooper Companies (COO) Bets on Fertility Growth Despite Weakness in CooperVision, we highlighted the company’s 1% year-over-year topline growth during the recently reported quarter, which […]

Citing “chronic underperformance,” Jana Partners is calling for new leadership and for the company to evaluate the sale of its fertility and medical device assets.

Hitting a new 52-week low can be a pivotal moment for any stock. These floors often mark either the beginning of a turnaround story or confirmation that a company faces serious headwinds.

For almost nine months, The Cooper Companies, Inc. (NASDAQ:COO) has been trying to sell its CooperSurgical unit. But on September 9, 2026, the company ended the strategic review it had launched in December 2025 and decided to keep the business. The reason is that the bids received were not in shareholders’ interest and reflected a […]

Healthcare stocks declined late Friday afternoon, with the NYSE Healthcare Index and the State Stree

Healthcare stocks were lower Friday afternoon, with the NYSE Healthcare Index decreasing 0.5% and th

As Cooper Companies has lagged behind its industry peers over the past year, Wall Street analysts maintain a cautious outlook on its prospects.

The low valuation multiples for value stocks provide a margin of safety that growth stocks rarely offer. However, the challenge lies in determining whether these cheap assets are genuinely undervalued or simply on sale due to their potentially deteriorating business models.

Sept 18 () - Activist investor Jana Partners on Friday urged Cooper Companies to launch an external search for a ‌new CEO and consider asset sales, arguing recent missteps ‌have hurt investor confidence and weighed on the medical device maker's market value. Cooper ​had lowered its annual forecasts last week and ended a review of options for its CooperSurgical unit without a sale.

Cooper Cos. stock rises as activist investor Jana Partners calls for the company to search for a new CEO and sell a key business segment.

In September 2026, The Cooper Companies completed a broad strategic review, ultimately deciding to retain CooperSurgical after assessing potential sale offers, while also outlining revised capital allocation plans and operational initiatives for CooperVision and CooperSurgical. The Board cited temporary factors such as a new competitor in non-hormonal IUDs and the impact of recent fertility litigation settlements as reasons for a perceived valuation gap that made selling CooperSurgical less...

The medical devices maker took a 5% hit on its stock before two big pieces of news—a guidance cut and the decision not to sell its women’s health business.

Wall Street is overwhelmingly bullish on the stocks in this article, with price targets suggesting significant upside potential. However, it’s worth remembering that analysts rarely issue sell ratings, partly because their firms often seek other business from the same companies they cover.

The Cooper Companies, Inc. (NASDAQ:COO) cut its fiscal 2026 profit and revenue forecasts after weaker-than-expected demand for contact lenses weighed on its CooperVision business. The company now expects adjusted earnings of $4.51–$4.55 per share, down from its previous forecast of $4.58–$4.66, while revenue guidance was reduced to $4.23–$4.25 billion from $4.29–$4.32 billion. Third-quarter revenue came in […]

Examine The Cooper Companies' (COO) international revenue patterns and their implications on Wall Street's forecasts and the prospective trajectory of the stock.

The Standard & Poor's 500 index slipped 0.8% this week, led to the downside by the health care and m

The Cooper Companies Inc. (NASDAQ:COO), a leading medical device company, announced its third quarter fiscal 2026 results on September 9. Topline went up 1% to $1.066 billion in comparison with the same quarter last year, which also included 1% organic growth. The company posted quarterly adjusted diluted EPS of $1.15, which represented a 4% jump […]

Medical device company CooperCompanies (NASDAQ:COO) missed Wall Street’s revenue expectations in Q2 CY2026, with sales flat year on year at $1.07 billion. The company’s full-year revenue guidance of $4.24 billion at the midpoint came in 1.5% below analysts’ estimates. Its non-GAAP profit of $1.15 per share was 2.7% above analysts’ consensus estimates.

Shares of medical device company CooperCompanies (NASDAQ:COO) fell 13.9% in the afternoon session after the company reported weak second-quarter results impacted by channel inventory destocking and decided to retain its CooperSurgical business.

(Updates with index/price moves, macroeconomic data and company/geopolitical news from the first par

US equity indexes ended lower Thursday after crude oil surged and government bond yields rose. *

(Updates with market moves at the end of the day, and other changes, if any.) Stocks on Wall Stre

Investors hammered Cooper Companies on Thursday after the medtech's fiscal third-quarter sales lagged Wall Street's expectations.

Healthcare stocks declined late Thursday afternoon, with the NYSE Healthcare Index shedding 0.3% and

Cooper won't sell its Surgical arm, and it was forced to cut forward guidance. Wall Street didn't like that.

Cooper Cos. stock has fallen about 25% since Barron’s recommended it, but a low valuation, aggressive share buybacks, and takeover potential bolster the bull case.

(Updates with latest market prices and developments.) Wall Street's main equity indexes were lowe

As the Q1 earnings season comes to a close, it’s time to take stock of this quarter’s best and worst performers in the medical devices & supplies - diversified industry, including CooperCompanies (NASDAQ:COO) and its peers.

Cooper Companies (NASDAQ:COO) reported third-quarter fiscal 2026 revenue of $1.066 billion, up about 1% on both a reported and organic basis, as record free cash flow and earnings growth offset pressure at its CooperVision contact lens business from planned U.S. channel inventory reductions. Non-GA

While the top- and bottom-line numbers for The Cooper Companies (COO) give a sense of how the business performed in the quarter ended July 2026, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

The Cooper Companies (COO) delivered earnings and revenue surprises of +3.60% and -2.97%, respectively, for the quarter ended July 2026. Do the numbers hold clues to what lies ahead for the stock?

Investing.com -- CooperCompanies (NASDAQ:COO) shares plunged 15% in after-hours trading Wednesday after the medical device company reported third-quarter results that missed revenue expectations and issued fourth-quarter and full-year guidance significantly below analyst estimates.

Cooper Companies (COO) reported fiscal Q3 adjusted earnings late Wednesday of $1.15 per diluted shar

Medical device company CooperCompanies (NASDAQ:COO) fell short of the market’s revenue expectations in Q2 CY2026, with sales flat year on year at $1.07 billion. The company’s full-year revenue guidance of $4.24 billion at the midpoint came in 1.5% below analysts’ estimates. Its non-GAAP profit of $1.15 per share was 2.7% above analysts’ consensus estimates.

COO Q3 earnings are likely to benefit from CooperVision strength, improving fertility trends and efficiency gains offsetting Asia-Pacific pressure.

US equity futures were tracking in the red on Wednesday while oil prices rose as the US and Iran exc

Medical device company CooperCompanies (NASDAQ:COO) will be reporting earnings this Wednesday after market close. Here’s what to expect.

Looking beyond Wall Street's top-and-bottom-line estimate forecasts for The Cooper Companies (COO), delve into some of its key metrics to gain a deeper insight into the company's potential performance for the quarter ended July 2026.

Many investors pay attention to mid-cap stocks because they have established business models and expansive market opportunities. However, their paths to becoming $100 billion corporations are ripe with competition, ranging from giants with vast resources to agile upstarts eager to disrupt the status quo.

Cooper Companies has underperformed the broader market over the past year, and analysts remain somewhat optimistic about the stock’s prospects.

Personal health and wellness is one of the many secular tailwinds for healthcare companies. Players catalyzing medical advancements have benefited from elevated demand, and their momentum is only rising as the industry has posted a 28.9% gain over the past six months, beating the S&P 500 by 18 percentage points.

COO vs. MMSI: Which Stock Is the Better Value Option?

Analyst projections of slower revenue growth for Cooper Companies (COO), along with past growth projects that did not clear the healthcare sector’s cost of capital, have put the stock’s recent underperformance in sharper focus for investors. See our latest analysis for Cooper Companies. Over the past year Cooper Companies has seen some recovery in its share price, with a 90 day share price return of 21.76% and a 1 year total shareholder return of 1.25%. However, the 3 year and 5 year total...

In recent months, CooperCompanies has faced a softer outlook as analysts now expect its revenue to grow more slowly than in prior years, pointing to potential demand challenges. An important underlying issue is that past growth investments have generated returns below the healthcare industry’s cost of capital, raising fresh questions about how efficiently management is deploying capital. Next, we’ll examine how this weaker revenue growth outlook and capital efficiency concern could reshape...

Cooper Companies stock has delivered a decline of 31.3% over the past five years, yet the current valuation picture is split, with a Discounted Cash Flow (DCF) intrinsic value estimate pointing to attractive upside while earnings based multiples suggest the shares are on the expensive side. Over five years, Cooper Companies has fallen 31.3%, which means long term holders are still under water even after more recent gains. The key support for the current valuation is the market's confidence...

Over the last six months, CooperCompanies’s shares have sunk to $75.74, producing a disappointing 9.5% loss - a stark contrast to the S&P 500’s 12.9% gain. This may have investors wondering how to approach the situation.

Cooper Companies' 22% three-month surge reflects contact lens share gains, MiSight growth and a recovering fertility business.